Cargando…

Daily, Once-Weekly, or No Asthma Controller Therapy At All: The Annoying Issue with Disease Remission in Clinical Asthma Trials

Detalles Bibliográficos
Autor principal:	Bahmer, Thomas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Thoracic Society 2021
Materias:	Editorials
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7874318/ https://www.ncbi.nlm.nih.gov/pubmed/33030964 http://dx.doi.org/10.1164/rccm.202008-3161ED

Ejemplares similares

Is once enough? Understanding the preferences of COPD and asthma patients for once- versus twice-daily treatment
por: Horne, Rob
Publicado: (2013)

Randomised trial of once-daily vilanterol in children with asthma on inhaled corticosteroid therapy
por: Oliver, Amanda J., et al.
Publicado: (2016)

Once-daily fluticasone furoate 50 mcg in mild-to-moderate asthma: a 24-week placebo-controlled randomized trial
por: Busse, W W, et al.
Publicado: (2014)

Efficacy and safety of once-daily single-inhaler triple therapy in patients with inadequately controlled asthma: the CAPTAIN trial
por: Ojanguren, Iñigo, et al.
Publicado: (2021)

Efficacy in asthma of once-daily treatment with fluticasone furoate: a randomized, placebo-controlled trial
por: Woodcock, Ashley, et al.
Publicado: (2011)

Efficacy and safety of once-daily fluticasone furoate 50 mcg in adults with persistent asthma: a 12-week randomized trial
por: O’Byrne, Paul M, et al.
Publicado: (2014)

How different is the once-weekly teriparatide from the daily one or the same?
por: Takeuchi, Yasuhiro
Publicado: (2019)

Characteristics of patients preferring once-daily controller therapy for asthma and COPD: a retrospective cohort study
por: Price, David, et al.
Publicado: (2013)

Once-daily fluticasone furoate alone or combined with vilanterol in persistent asthma
por: O’Byrne, Paul M., et al.
Publicado: (2014)

Pediatric Asthma: A Daily Challenge
por: Ciprandi, Giorgio
Publicado: (2022)

Fluticasone furoate: once-daily evening treatment versus twice-daily treatment in moderate asthma
por: Woodcock, Ashley, et al.
Publicado: (2011)

Integrated safety and efficacy analysis of once-daily fluticasone furoate for the treatment of asthma
por: O’Byrne, Paul M., et al.
Publicado: (2016)

Spotlight on fluticasone furoate/vilanterol trifenatate for the once-daily treatment of asthma: design, development and place in therapy
por: Albertson, Timothy E, et al.
Publicado: (2016)

Once-daily fluticasone furoate/vilanterol versus twice daily combination therapies in asthma–mixed treatment comparisons of clinical efficacy
por: Svedsater, Henrik, et al.
Publicado: (2016)

Bronchial asthma - Issues for the developing world
por: Behera, D., et al.
Publicado: (2015)

Special Issue on ‘Asthma and Allergic Inflammation’
por: Pelaia, Corrado
Publicado: (2023)

Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis
por: Kamm, M A, et al.
Publicado: (2008)

Once-daily fluticasone furoate/vilanterol combination versus twice-daily budesonide/formoterol combination in the treatment of controlled stable asthma: a randomized crossover trial
por: Furuhashi, Kazuki, et al.
Publicado: (2019)

Anticholinergics in asthma: are we utilizing asthma therapies effectively?
por: Vogelberg, Christian
Publicado: (2019)

Editorial of Special Issue “Molecular Mechanisms of Allergy and Asthma”
por: Potaczek, Daniel P.
Publicado: (2021)

Editorial to the Special Issue “Pathogenesis and Novel Therapeutics in Asthma”
por: Bazan-Socha, Stanisława, et al.
Publicado: (2023)

Special Issue “Diagnosis, Treatment, and Management of COPD and Asthma”
por: Nishimura, Koichi
Publicado: (2023)

Editorial for “Asthma and Its Impact in Adolescents” Special Issue
por: Dal Negro, Roberto W.
Publicado: (2023)

Effect of once-daily indacaterol maleate/mometasone furoate on exacerbation risk in adolescent and adult asthma: a double-blind randomised controlled trial
por: Beasley, Richard W, et al.
Publicado: (2015)

Pharmacodynamics and Pharmacokinetics Following Once-Daily and Twice-Daily Dosing of Tiotropium Respimat(®) in Asthma Using Standardized Sample-Contamination Avoidance
por: Beeh, Kai-Michael, et al.
Publicado: (2016)

Modelling the effect of beliefs about asthma medication and treatment intrusiveness on adherence and preference for once-daily vs. twice-daily medication
por: Chapman, Sarah, et al.
Publicado: (2017)

Long-Term Once-Daily Tiotropium Respimat® Is Well Tolerated and Maintains Efficacy over 52 Weeks in Patients with Symptomatic Asthma in Japan: A Randomised, Placebo-Controlled Study
por: Ohta, Ken, et al.
Publicado: (2015)

Maintaining remission in ulcerative colitis – role of once daily extended-release mesalamine
por: Oliveira, Lilliana, et al.
Publicado: (2011)

Inflammatory Remission in T2 Severe Asthma
por: Rial, Manuel J., et al.
Publicado: (2022)

Asthma remission: what is it and how can it be achieved?
por: Thomas, Dennis, et al.
Publicado: (2022)

To Our Editorial Brethren—Postal Annoyances
Publicado: (1877)

Once-daily fluticasone furoate (FF)/vilanterol reduces risk of severe exacerbations in asthma versus FF alone
por: Bateman, Eric D, et al.
Publicado: (2014)

Safety of Once-Daily Single-Inhaler Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol in Japanese Patients with Asthma: A Long-Term (52-Week) Phase III Open-Label Study
por: Hozawa, Soichiro, et al.
Publicado: (2021)

Patients' preferences for once‐daily oral versus once‐weekly injectable diabetes medications: The REVISE study
por: Boye, Kristina, et al.
Publicado: (2020)

The Short-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Sitagliptin and Once-Weekly Dulaglutide for the Treatment of Patients with Type 2 Diabetes: A Cost of Control Analysis in Spain
por: Vidal, Josep, et al.
Publicado: (2020)

Assessing small airways dysfunction in asthma, asthma remission and healthy controls using particles in exhaled air
por: Carpaij, Orestes A., et al.
Publicado: (2019)

Asthma attacks in children are always preceded by poor asthma control: myth or maxim?
por: De Keyser, Heather H., et al.
Publicado: (2020)

Editorial of Special Issue “Molecular Mechanisms of Allergy and Asthma 2.0”
por: Potaczek, Daniel P.
Publicado: (2023)

Adherence to GLP-1 receptor agonist therapy administered by once-daily or once-weekly injection in patients with type 2 diabetes in Germany
por: Qiao, Qing, et al.
Publicado: (2016)

Level of asthma control and its impact on activities of daily living in asthma patients in Brazil
por: Gazzotti, Mariana Rodrigues, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_f265b06q30e1ck4p3161f9i06t